The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation. Delcath Systems Inc. (DCTH) Delcath Systems is an interventional oncology company focused on developing therapies for primary and...
Delcath Systems Inc. (DCTH) released a profit for second quarter of $2.67 million The company's earnings came in at $2.67 million, or $0.07 per share. This compares with $2.70 million, or $0.07 per share, last year. The company's revenue for the period rose 20.6% to $29.13 million from $24.16...
Delcath Systems Inc. (DCTH) is drawing attention after new subgroup analyses from its Phase 3 FOCUS study showed consistent tumor responses across nearly all patient categories, reinforcing the clinical value of its FDA-approved HEPZATO KIT for unresectable metastatic uveal melanoma.
Trading after the bell was relatively muted on Thursday, with small-cap biotech names showing modest shifts. Delcath Systems edged higher following its buyback announcement, while BioVie, Cassava Sciences, and Enlivex Therapeutics rebounded despite a lack of fresh headlines. Delcath Systems, Inc....
Delcath Systems Inc. (DCTH) reported earnings for third quarter that Dropped, from the same period last year but beat the Street estimates. The company's bottom line came in at $0.83 million, or $0.02 per share. This compares with $1.86 million, or $0.06 per share, last year. Analysts on average...
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.